Aurinia Pharmaceuticals Inc (AUPH): Valuation
TTM figures as of June 30, 2026
Aurinia Pharmaceuticals Inc trades at 6.8 times trailing earnings. On P/E that is higher than 33% of its own month-end history back to 2019. The Healthcare median P/E is 22.9.
Earnings yield 14.66%. Shareholder yield 3.88%. ROIC 30.4%. Piotroski F-score 7 of 9. Net cash $119.3M.
78 month-end valuation observations are on file, starting December 2019.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is AUPH cheap versus its own history?
Aurinia Pharmaceuticals Inc trades at 6.8 times trailing earnings. On P/E that is higher than 33% of its own month-end history back to 2019. The Healthcare median P/E is 22.9.
What is AUPH's free-cash-flow yield?
Free-cash-flow yield is trailing free cash flow divided by the live market cap. It is omitted when free cash flow is missing.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.